The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study

The substantial morbidity and mortality associated with refractory systemic JIA underlies the need for new treatment approaches. However, progress in this area has been limited by the difficulty of enrolling t...

Source: Pediatric Rheumatology - January 3, 2024 Category: Rheumatology Authors: Fabrizio de Benedetti, Alexei A. Grom and Hermine Brunner Tags: Meeting report Source Type: research